Advanced case of PKDL due to delayed treatment: A rare case report.

Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is thought to be the potential reservoir of parasite. Miltefosine (MF) is the only oral drug existing for treatment of post-kala-azar dermal leishmaniasis (PKDL). Increased miltefosine tolerance in clin...

Full description

Bibliographic Details
Published in:PLOS Neglected Tropical Diseases
Main Authors: Roshan Kamal Topno, Vidya Nand Rabi Das, Maneesh Kumar, Major Madhukar, Krishna Pandey, Neena Verma, Kanhaiya Agrawal, Chandra Shekhar Lal, Niyamat Ali Siddiqui, Sanjiva Bimal, Pradeep Das
Format: Article in Journal/Newspaper
Language:English
Published: Public Library of Science (PLoS) 2020
Subjects:
Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Arctic
Azar
Online Access:https://doi.org/10.1371/journal.pntd.0008052
https://doaj.org/article/b88af5d0cffe4b4ea35d04fd5a2cede7
Description
Summary:Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is thought to be the potential reservoir of parasite. Miltefosine (MF) is the only oral drug existing for treatment of post-kala-azar dermal leishmaniasis (PKDL). Increased miltefosine tolerance in clinical isolates of Leishmania donovani has been reported and is one of the major concerns in the treatment of PKDL. Here, we report a highly ulcerated PKDL case that was successfully cured after miltefosine treatment.

Similar Items